Mendaera, a Silicon Valley-based company, develops medical robotic technology. Its platform combines robotics, real-time imaging, AI and connectivity to enable intervention at scale. The company recently completed the research and design process for its novel robotic system and added $24 million in Series A funding in August.
Butterfly Network and Mendaera agreed to commercialize a novel robotic system powered by Butterfly’s Ultrasound-on-Chip technology. The Burlington, Massachusetts–based company develops the technology for handheld ultrasound and recently announced a foray into brain-computer interfaces.
Mendaera’s technology is compatible with Butterfly’s ultrasound device, according to a news release, and connected by the company’s Butterfly Garden software development kit. They aim to create a system capable of improving precision and consistency for image-guided, needle-based interventions.
Butterfly said the new category of robotics could increase access to high-quality interventional treatment. They expect to submit to the FDA by 2025. Upon commercialization, the companies agreed to include a revenue share for every unit sold.
Josh DeFonzo, Mendaera co-founder and CEO, called the decision to work with Butterfly “a clear choice.” DeFonzo said the unique, programmable platform could make ultrasonic imaging and intervention ubiquitous.
“Mendaera’s robotic system is perfectly suited to leverage Butterfly’s proprietary Ultrasound-on-Chip by benefiting from the wide array of ultrasonic sensing applications that only our chip can offer,” said Darius Shahida, chief strategy officer of Butterfly Network. “We are excited to welcome the Mendaera team as a ‘Powered by Butterfly’ partner and believe our joint solution will expand Butterfly’s reach and clinical impact into the interventional space.”
